daz999999999
01-06

Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.

Company Symbol Quarter Mean Report Time

·Tuesday

·Aar Corp. $(AIR)$ 2Q 1.04 4:05 PM

·AngioDynamics $(ANGO)$ 2Q (.10) BMO

·Penguin Solutions $(PENG)$ 1Q .44 4:05 PM

·

·Wednesday

·Albertsons Cos $(ACI)$ 3Q .68 7:30 AM

·Apogee Enterp. $(APOG)$ 3Q 1.02 BMO

·Applied Digital Corp (APLD) 2Q (.11) 4:05 PM

·AZZ Inc. $(AZZ)$ 3Q 1.47 AMC

·Cal-Maine Foods (CALM) 2Q 1.95 6:00 AM

·Constellation Brands $(STZ)$ 3Q 2.64 AMC

·Franklin Covey Co. $(FC)$ 1Q .04 AMC

·Jefferies Fincl $(JEF)$ 4Q .94 4:15 PM

·Kura Sushi USA (KRUS) 1Q (.15) AMC

·MSC Indus Direct $(MSM)$ 1Q .95 6:30 AM

·PriceSmart Inc. $(PSMT)$ 1Q 1.35 AMC

·Resources Connctn $(RGP)$ 2Q (.01) 4:05 PM

·Saratoga Invest $(SAR)$ 3Q .59 AMC

·UniFirst Corp. $(UNF)$ 1Q 2.06 8:00 AM

·

·Thursday

·Acuity Inc. $(AYI)$ 1Q 4.57 6:00 AM

·Aehr Test Syss (AEHR) 2Q (.05) 4:05 PM

·Commercial Metals $(CMC)$ 1Q 1.57 BMO

·Concrete Pumping (BBCP) 4Q .09

·Greenbrier Cos Inc. $(GBX)$ 1Q .79 4:15 PM

·Helen of Troy Ltd $(HELE)$ 3Q 1.69 6:45 AM

·Lindsay Corp. $(LNN)$ 1Q 1.47 BMO

·Neogen Corp $(NEOG)$ 2Q .06 7:00 AM

·RPM Intl $(RPM)$ 2Q 1.41 6:45 AM

·Simply Good Foods (SMPL) 1Q .36 BMO

·Simulations Plus Inc. (SLP) 1Q .19 4:05 PM

·TD SYNNEX Corp $(SNX)$ 4Q 3.73 BMO

·Tilray Brands Inc. $(TLRY)$ 2Q (.21) AMC

·WaFd Inc.               

@daz999999999：
$Genprex, Inc.(GNPX)$ GNPX (Genprex) forecasts show mixed signals, with some analysts projecting potential upside with a ~ $7.50 target despite current weakness, while others highlight significant risks like cash burn and reliance on clinical trial success, with fair value estimates suggesting the stock is overvalued or facing a "going concern" risk, indicating high volatility and uncertainty, especially given ongoing clinical trial progress. Analyst Ratings & Price Targets Strong Buy/Buy: Some analysts rate it a "Strong Buy," with one 12-month target around $7.50 - $7.88, seeing potential upside from current levels, according to MarketBeat and Fintel, sources 1, 2, 8. Sell/Hold: Other analyses lean negative due to financial health concerns, with some pointing to a "Sell" consensus and negative fair value projections, notes MarketBeat and StockInvest.us, sources 6, 7. Key Factors Influencing Forecasts Clinical Trials: The success of its lead candidate, Reqorsa Immunogene Therapy, in cancer trials (like Acclaim-3) is crucial, notes Yahoo Finance and Simply Wall St, sources 3, 14. Financial Health: Severe cash constraints and reliance on equity financing raise "going concern" risks, leading to dilution and potential for weak performance, as shown by Trefis and Chartmill, sources 5, 12. Valuation: Intrinsic value estimates often suggest the stock is overvalued compared to its current market price, as seen on Alpha Spread, source 10. Overall Sentiment Expect high volatility, as the stock trades near its 52-week low but has seen positive clinical updates, states CNN and Simply Wall St, sources 11, 14. The future hinges heavily on clinical trial outcomes and Genprex's ability to manage its finances and avoid further dilution, say Trefis and Value Investing IO, sources 5, 9.
$Genprex, Inc.(GNPX)$ GNPX (Genprex) forecasts show mixed signals, with some analysts projecting potential upside with a ~ $7.50 target despite current weakness, while others highlight significant risks like cash burn and reliance on clinical trial success, with fair value estimates suggesting the stock is overvalued or facing a "going concern" risk, indicating high volatility and uncertainty, especially given ongoing clinical trial progress. Analyst Ratings & Price Targets Strong Buy/Buy: Some analysts rate it a "Strong Buy," with one 12-month target around $7.50 - $7.88, seeing potential upside from current levels, according to MarketBeat and Fintel, sources 1, 2, 8. Sell/Hold: Other analyses lean negative due to financial health concerns, with some pointing to a "Sell" consensus and negative fair value projections, notes MarketBeat and StockInvest.us, sources 6, 7. Key Factors Influencing Forecasts Clinical Trials: The success of its lead candidate, Reqorsa Immunogene Therapy, in cancer trials (like Acclaim-3) is crucial, notes Yahoo Finance and Simply Wall St, sources 3, 14. Financial Health: Severe cash constraints and reliance on equity financing raise "going concern" risks, leading to dilution and potential for weak performance, as shown by Trefis and Chartmill, sources 5, 12. Valuation: Intrinsic value estimates often suggest the stock is overvalued compared to its current market price, as seen on Alpha Spread, source 10. Overall Sentiment Expect high volatility, as the stock trades near its 52-week low but has seen positive clinical updates, states CNN and Simply Wall St, sources 11, 14. The future hinges heavily on clinical trial outcomes and Genprex's ability to manage its finances and avoid further dilution, say Trefis and Value Investing IO, sources 5, 9.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet